Table 4.
Methionine near the end of H3.
| Name | % Native Fd | Observed oxidation event(s) | Predicted oxidation event(s) | Number of Fd methionine | H3 sequence | Predicted % SASA for H100 methionine |
|---|---|---|---|---|---|---|
| tocilizumab | 0 | 1 | 0 | 2 | ARSLARTTAMDY | 2 |
| eldelumab | 0 | 2 | 2 | 5 | AREGDGSGIYYYYGMDV | 1 |
| dinutuximab | 0 | 2 | 2 | 4 | VSGMEY | 11 |
| vesencumab | 0 | 2 | 1 | 4 | ARGELPYYRMSKVMDV | 2 |
| lirilumab | 4 | 1 | 0 | 3 | ARIPSGSYYYDYDMDV | 2 |
| imgatuzumab | 5 | 1 | 0 | 3 | ARLSPGGYYVMDA | 4 |
| trastuzumab | 44 | 1 | 0 | 2 | SRWGGDGFYAMDY | 2 |
| lebrikizumab | 60 | 0 | 0 | 4 | AGDGYYPYAMDN | 7 |
| robatumumab | 64 | 0 | 0 | 3 | ARLGNFYYGMDV | 2 |
| parsatuzumab | 65 | 0 | 0 | 3 | AREGVYHDYDDYAMDY | 4 |
| tremelimumab | 74 | 0 | 0 | 3 | ARDPRGATLYYYYYGMDV | 1 |
| fresolimumab | 77 | 0 | 0 | 3 | ASTLGLVLDAMDY | 3 |
| girentuximab | 82 | 0 | 0 | 3 | ARHRSGYFSMDY | 3 |
| certolizumab | 88 | 0 | 0 | 4 | ARGYRSYAMDY | 4 |
| ofatumumab | 97 | 0 | 0 | 3 | AKDIQYGNYYYGMDV | 1 |
| tovetumab | 100 | 0 | 0 | 3 | AREGRIAARGMDV | 2 |
| natalizumab | 100 | 0 | 0 | 3 | AREGYYGNYGVYAMDY | 2 |
| lintuzumab | 100 | 0 | 0 | 3 | ARGRPAMDY | 6 |
| golimumab | 100 | 0 | 0 | 4 | ARDRGIAAGGNYYYYGMDV | 2 |
| abituzumab | 100 | 0 | 0 | 4 | ASFLGRGAMDY | 3 |
| duligotuzumab | 100 | 0 | 0 | 2 | ARESRVSFEAAMDY | 1 |
| fletikumab | 100 | 0 | 0 | 3 | AREPLWFGESSPHDYYGMDV | 1 |